1. Scrip
  2. >>Archive

New Approaches for Neurodegenerative Disorders

 
• By Jeff Dvorin

Neurodegenerative disorders represent a tremendous unmet medical need. Millions of people are affected by such diseases as Alzheimer's, Huntington's Parkinson's, MS and ALS, not to mention those suffering the neurodegenerative effects of stroke and spinal cord injury. And because many of these diseases are age-related, the already staggering numbers of patients will increase during the next several years as increasing life expectancies and changing demographics increase the percentage of older Americans. The market for neuroscience therapies is currently the fastest growing segment in pharmaceuticals, and is projected to become the leading therapeutic area within five years. Small wonder that new companies are entering the fray, hoping to capture a share of this multi-billion dollar opportunity as well as to finally offer a cure to the victims of these diseases.

Neurodegenerative disorders represent a tremendous unmet medical need. Millions of people are affected by such diseases as Alzheimer's, Huntington's Parkinson's, MS and ALS, not to mention those suffering the neurodegenerative effects of stroke and spinal cord injury. And because many of these diseases are age-related, the already staggering numbers of patients will increase during the next several years as increasing life expectancies and changing demographics increase the percentage of older Americans. Thirteen percent of the US population (more than 34 million individuals) is age 65 or older; according to the US Bureau of the Census, this figure will rise to 18% by 2025. The number of Americans over age 85 will more than double by 2030 according to Bureau estimates.

Researchers have yet to discover the underlying causes of many of these diseases. And the marketed therapeutics generally act to...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

Final Chance To Have Your Say: Take Scrip's Reader Survey This Week

 
• By Eleanor Malone

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 
• By Eleanor Malone

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access Scrip, or if you love it how it is, now is the time to have your voice heard.

Galapagos Expands Point-Of-Care CAR-T Study To The US

 
• By Andrew McConaghie

CEO Paul Stoffels said gaining US clearance for an IND for its novel CAR-T product was demanding, but now opens up a pathway towards a pivotal study starting in 2025.

Analysts Split On Eisai’s Chances Of Changing EU Regulator’s Mind On Leqembi

 
• By Andrew McConaghie

A final rejection of Leqembi could also spell the same fate for Lilly’s rival drug but public outcry and demand for Alzheimer’s therapies might force the regulator’s hand

More from Scrip

Immuneering Could Partner Atebimetinib Or Go It Alone After Phase IIa Success

 
• By Alaric DeArment

CEO Ben Zeskind said all options are on the table after atebimetinib showed impressive results in pancreatic cancer.

Lilly Agrees To Acquire PCSK9 Base-Editing Partner Verve

 
• By Joseph Haas

Instead of opting in on Phase II-ready PCSK9-targeted VERVE-102, Lilly will buy its partner for up to $1.3bn. Analysts call the deal a bargain for Lilly, but fair to Verve.

Enliven Raises $230m To Fund Scemblix Leukemia Challenger

 
• By Andrew McConaghie

The company believes its drug could eventually displace Novartis’s Scemblix in first-line chronic myeloid leukemia treatment, but for now is preparing for a second-/third-line pivotal study.